Mild Cognitive Impairment Clinical Trial
— MCIOfficial title:
A Randomized Double-Blinded Placebo-Controlled Exploratory Study of Intravenous Immunoglobulin (NewGam 10%) in Amnestic Mild Cognitive Impairment
Verified date | July 2022 |
Source | Sutter Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with mild cognitive impairment (MCI) are a group recognized at being at high risk of progressing to Alzheimer disease. Treatment of MCI with immunotherapy with intravenous immunoglobulins (IVIG) could potentially reduce the risk of progression to Alzheimer disease. This study will evaluate the efficacy of intravenous immunoglobulin in patients with MCI over 24 months after the first infusion. This study will also document conversion from MCI to Alzheimer's Disease.
Status | Completed |
Enrollment | 52 |
Est. completion date | March 12, 2020 |
Est. primary completion date | March 12, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 84 Years |
Eligibility | Inclusion Criteria: 1. Age from 50 to < 85 years old. 2. Diagnosis of Mild Cognitive Impairment, Amnestic type (single or multi domain) according to Petersen criteria (Appendix B) and supported by a CDR score of 0.5. 3. Mini-Mental State Examination (MMSE) score of 24-30, inclusive. 4. Rosen Modified Hachinski Ischemic score = 4. 5. Willing to consent to Apolipoprotein E (ApoE) testing and agree to disclose Apolipoprotein E4 (ApoE4) status. Previous ApoE testing will be accepted. 6. Receiving stable doses of medication(s) for the treatment of non-excluded medical condition(s) for at least 30 days prior to screening. 7. Ability to attend all clinical visits and have an informant capable of accompanying the subject on specific clinic visits for two years or the duration of the study. 8. The subject's collaborative informant (support person) must be someone who has known the subject for at least 4 years; agrees to have at least 2 separate communications with the study participant per month for the duration of the study (one of these communications must be in person); and attends and completes the CDR interview at 8 study visits along with the subject. 9. Fluency in English and evidence of adequate premorbid intellectual functioning. 10. Adequate manual dexterity, visual, and auditory abilities to perform all aspects of the cognitive and functional assessments. 11. Venous access suitable for repeated infusion and phlebotomy. Exclusion criteria: 1. Has significant neurological disease, other than a-MCI that may affect cognition. 2. History of clinically evident stroke or history of clinically significant carotid or vertebrobasilar stenosis or plaque. 3. History of seizures, excluding febrile seizures in childhood. 4. Brain MRI shows moderate or severe cortical or hippocampal atrophy. 5. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, CSF shunts, claustrophobia, metal fragments or foreign objects in the eyes, skin, or body that would contraindicate a brain MRI scan. 6. Current presence of a clinically significant major psychiatric disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR). 7. History of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma, and squamous cell carcinoma of the skin. 8. Uncontrolled hypertension (diastolic BP> 100 mmHg or systolic BP> 160 mmHg, sitting). 9. History or evidence of any clinically significant autoimmune disease or disorder of the immune system (eg., Crohn's Disease, Rheumatoid Arthritis) 10. Women of childbearing potential. 11. Weight greater than 120 kg (264 lbs). 12. Excessive smoking defined as more than 20 cigarettes per day. 13. History of alcohol or drug dependence or abuse as defined by DSM-IV criteria within the last 2 years. 14. Severe liver or kidney disease verified by the PI review of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine. 15. Known coagulopathy, thrombosis, or low platelet count. 16. Known deficiency to Immunoglobulin A (IgA). 17. Positive serology for Hepatitis B or C, or HIV. 18. Concurrent or prior treatment with cholinesterase inhibitors and/or memantine, or Axona for cognitive enhancement. Exceptions (e.g. brief exposure to one of these medications) may be authorized if agreed upon by PI and sub-I. 19. Concurrent use of anticholinergic drugs including diphenhydramine. 20. Current use of anticonvulsant drugs for seizures, antiparkinson drugs, anticoagulant medications (except the use of aspirin 325 mg/day or less, plavix, aggrenox, and persantine but not for stroke). 21. Concurrent use of opioid pain relievers and related synthetic derivatives. 22. Use of experimental medications for AD or any other investigational medications or devices within 60 days prior to screening or within 5 half-lives of use of such a medication prior to screening, whichever is longer. 23. Prior treatment with IVIG or other experimental immunotherapeutic or vaccine for MCI or AD, or prior treatment with a biological product for the treatment of a-MCI or AD. |
Country | Name | City | State |
---|---|---|---|
United States | Sutter Neuroscience Medical Group | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
Sutter Health |
United States,
Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Chan M, Ghassemi A. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to deme — View Citation
Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009 Nov;30(11):1728-36. doi: 10.1016/j.neurobiolaging.2007.12.021. Epub 2008 Feb 21. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Annualized Percent Change in Ventricular Volume (APCV) as Measured by MRI | Change in ventricular volumetric as measured by MRI at baseline, 12, and 24 months following the first infusion of either 0.4 g/kg NewGam or 0.9% saline solution(placebo) every 14 days x 5. Participants will also be classified as early MCI (EMCI) if baseline CDR-SB is less than 1.5, and late MCI (LMCI) if CDR-SB is greater than or equal to 1.5. |
Baseline, 12, and 24 month MRI evaluation | |
Secondary | Number of Participants Who Converted From Amnestic Mild Cognitive Impairment (a-MCI) to Alzheimer Disease (AD) | The National Institute of Neurological and Communicative Disorders and Stroke - Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA) Alzheimer's Criteria were proposed in 1984 by NINCDS-ADRDA criteria for diagnosing Alzheimer Disease and Clinical Dementia Rating (CDR) will be used to determine conversion from a-MCI to AD. | Baseline to 24 months | |
Secondary | Change in Ventricular Volume in Patients With Positive Cerebrospinal Fluid (CSF) Aß1-42/CSF P-Tau181P Alzheimer Signature | Mean ventricular volume (cubic centimeters) in patients with positive cerebrospinal fluid (CSF) Aß1-42/CSF P-Tau181P Alzheimer signature at 24 months following infusion | Baseline to 24 months following infusion | |
Secondary | Mean Cognitive Performance at 12 Months | 12 month cognitive performance in treatment (IVIG/placebo) is measured by: Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog) Scale from 0 to 85 (0 is best cognitive performance) Score is the sum of 12 sub-scales. Mini Mental State Exam (MMSE) Scale from 0 to 30 (30 is best cognitive performance) Score is the sum of 11 sub-scales. Clinical Dementia Rating - Sum of Boxes (CDR-SB) Scale is 0 to 18 (0 is best cognitive performance) Score is the sum of 6 sub-scales |
12 months | |
Secondary | Mean Cognitive Performance at 24 Months | 24 month cognitive performance in treatment (IVIG/placebo) is measured by: Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog) Scale from 0 to 85 (0 is best cognitive performance) Score is the sum of 12 sub-scales. Mini Mental State Exam (MMSE) Scale from 0 to 30 (30 is best cognitive performance) Score is the sum of 11 sub-scales. Clinical Dementia Rating - Sum of Boxes (CDR-SB) Scale is 0 to 18 (0 is best cognitive performance) Score is the sum of 6 sub-scales |
24 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |